A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

Recruiting

Phase 1

Phase 2

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

Sponsor:

Clarametyx Biosciences, Inc.

Code:

NCT06159725

Conditions

Persistent Infection

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CMTX-101

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-12. This information was provided to ClinicalTrials.gov by Clarametyx Biosciences, Inc. on 2025-01-27.